Why has the Medibank (ASX:MPL) share price leapt 8% in November so far?

Medibank shares have risen this month. What’s going on?

| More on:
Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.

Image source: Getty Images

The Medibank Private Limited (ASX: MPL) share price has gone up by 8% in this month alone. What could be impacting the sentiment about the private health insurer?

Medibank shares have been somewhat variable in recent months. It has gone up by 16% over the last six months and 8% this month. But it’s only back to where it was during September 2021.

Just last week, the company held its annual general meeting (AGM) and gave a presentation.

Medibank AGM update

The company reminded investors that COVID has put health at the top of the community’s mind. In FY21, it experienced “solid financial performance”, “strong policyholder growth, an increase in market share and record customer advocacy.”

It saw health insurance operating profit growth of 14.4%, with Medibank Health segment profit rising by 12.9%. This helped overall group net profit after tax increasing 39.8% to $441.2 million. That included investment income being $117 million above last year.

Medibank said that it’s focused on scaling and expanding its preventative health programs. It invested in Myhealth Medical Group of GP clinics this year, to support expanding the footprint and transforming the approach to providing preventative healthcare for patients.

In the longer-term, its focus on preventative health will be “key” to help ensure the overall sustainability of the health system.

FY22 and outlook comments

The outlook can have impacts on the Medibank share price.

Medibank said that it remains committed to returning any permanent net claims savings due to COVID back to customers and it expects to confirm its next wave of customer support before the “end of the year”.

One comment that investors may be focusing on is that Medibank has seen “strong policyholder growth” continue in the first four months of FY22, with another 21,000 policyholders added.

Medibank said it expects industry participation growth will be slower in FY22 compared to FY21, so it’s now aiming to achieve growth of at least 3%, including growth in the Medibank brand.

Taking into account the recent COVID lockdowns in Victoria and NSW, on an underlying basis, it’s expecting average net claims per policy unit to be in line with the second half of FY21, or 2.4% among resident policyholders.

The business also believes that it can cut $15 million of health insurance management expenses to improve productivity in FY22. It’s also targeting “inorganic” growth for Medibank Health and health insurance.

Is the Medibank share price a buy now?

Some brokers think so, though the price target doesn’t leave a lot of gains on the table.

The broker Morgan Stanley currently thinks that Medibank shares are a buy with a price target of $3.80 – that’s a potential upside of around 5% over the next 12 months.

There are several brokers that rate Medibank as a hold, such as Ord Minnett, which has a price target of $3.30.

Should you invest $1,000 in Medibank right now?

Before you consider Medibank, you'll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Medibank wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of January 13th 2022

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Imugene (ASX:IMU) share price leaps 10% on new Roche deal

Key Points Imugene shares rocket on back of new supply agreement with Roche Clinical trial of PD1-Vaxx will be combined …

Read more »

Lab technician analyses a sample in a laboratory for a clinical trial
Healthcare Shares

Race Oncology (ASX:RAC) share price rises following preclinical discovery

Key points The Race Oncology share price is up as high as 2.8% today A new discovery relating to heart …

Read more »

shocked man with hands over his face with a declining graph in background representing falling CleanSpace share price
Healthcare Shares

Why the AnteoTech (ASX:ADO) share price is plummeting 23% on Friday

Key Points AnteoTech shares sink on additional request for information by the TGA The company submitted a performance report last …

Read more »

Group of Imugene scientists cheering in the lab after the company received another patent for HER-Vaxx
Healthcare Shares

Why the Imugene (ASX:IMU) share price advanced 5% on market open

Key points Imugene share price soared 5% on the back of European patent approval This is further intellectual protection for …

Read more »

A healthcare worker wearing a white coat holds his fingers to his mouth looking worried as healthcare stocks like Cochlear crash today
Earnings Results

ResMed (ASX:RMD) share price on watch after Q2 update disappoints

Key points ResMed delivered solid revenue and profit growth in the second quarter A major competitor product recall boosted demand …

Read more »

Lab worker puts hands in the air and dances around
Healthcare Shares

Here’s why the Rhythm Biosciences (ASX:RHY) share price soared 8% today

Key points The Rhythm Biosciences share price finished the day up by more than 8% after earlier jumping by 19% …

Read more »

gloved hand holding covid-19 vaccine against backdrop of australian flag
Healthcare Shares

Own CSL (ASX:CSL) shares? Here’s why the company is moving on from COVID research

CSL Limited (ASX: CSL) shares are joining the broader ASX selloff today, down 3.93% to $248.20 per share. The S&P/ASX …

Read more »

Graph showing a fall in share price.
Healthcare Shares

Why is the Cochlear (ASX:COH) share price tumbling 5% on Thursday?

Key points Cochlear is one of the worst performing ASX 200 healthcare stocks on Thursday Right now, its share price …

Read more »